Last reviewed · How we verify
Topiramate IR
At a glance
| Generic name | Topiramate IR |
|---|---|
| Also known as | Topamax® |
| Sponsor | Supernus Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight (PHASE3)
- Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine (PHASE2)
- A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM) (PHASE1)
- Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topiramate IR CI brief — competitive landscape report
- Topiramate IR updates RSS · CI watch RSS
- Supernus Pharmaceuticals, Inc. portfolio CI